The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Testosterone] affects the activity of CYP19A1 protein 2,4,5,2',4',5'-hexachlorobiphenyl results in decreased activity of CYP19A1 protein
[2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Androstenedione] results in increased activity of HSD17B1 protein 2,4,5,2',4',5'-hexachlorobiphenyl results in decreased activity of HSD17B1 protein
Tetrachlorodibenzodioxin results in decreased expression of AHR mRNA Tetrachlorodibenzodioxin results in increased expression of AHR protein Tetrachlorodibenzodioxin affects the localization of AHR protein
3,4,5,3',4'-pentachlorobiphenyl results in increased expression of AHR protein epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of AHR protein]
CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; CAV1 mutant form promotes the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NQO1 mRNA]
3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA; 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 protein CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 protein]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]
3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP19A1 protein [3,4,5,3',4'-pentachlorobiphenyl co-treated with Testosterone] results in increased activity of CYP19A1 protein
epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein] 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA; 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK3 protein
NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]
3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NQO1 mRNA [epigallocatechin gallate co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased expression of NQO1 mRNA; CAV1 mutant form promotes the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NQO1 mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA] 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA; 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein
3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein; [alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [[alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein]
3,4,3',4'-tetrachlorobiphenyl results in increased expression of and results in increased phosphorylation of CAV1 protein; CAV1 mutant form inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of and results in increased phosphorylation of CAV1 protein]
3,4,3',4'-tetrachlorobiphenyl results in increased secretion of CCL2 protein 3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA [2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; [2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein]; [2,2'-azobis(2-amidinopropane) results in increased oxidation of Eicosapentaenoic Acid] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; [2,2'-azobis(2-amidinopropane) results in increased oxidation of Eicosapentaenoic Acid] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein]; Acetylcysteine inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; sodium borohydride inhibits the reaction [[2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]]; sulforaphane inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; Tretinoin promotes the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein]
3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein 3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA; 3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased phosphorylation of MAPK3 protein]
3,4,3',4'-tetrachlorobiphenyl results in increased activity of RELA protein [2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of RELA protein]
3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELE mRNA Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELE mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA] 3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA; 3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]]
Amiloride inhibits the reaction [[Asbestos, Crocidolite results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [[Asbestos, Serpentine results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]
Amiloride inhibits the reaction [[Asbestos, Crocidolite results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [[Asbestos, Serpentine results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [Asbestos, Crocidolite results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [Asbestos, Serpentine results in increased cleavage of PLG protein]
Bezafibrate inhibits the reaction [[Cisplatin results in decreased activity of PPARA protein] which results in increased abundance of Fatty Acids, Nonesterified]; Bezafibrate inhibits the reaction [Cisplatin results in decreased activity of PPARA protein]
Chloroquine results in increased expression of SQSTM1 protein Chloroquine inhibits the reaction [ochratoxin A results in decreased expression of SQSTM1 protein]
Chlortetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]
[ciprofibrate co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]
Clofibrate results in decreased expression of EDN1 protein Clofibrate inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [KNG1 protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EDN1 protein]; Nitric Oxide deficiency inhibits the reaction [Clofibrate results in decreased expression of EDN1 protein]
Clofibrate results in increased expression of NOS3 protein calphostin C inhibits the reaction [Clofibrate results in increased expression of NOS3 protein]
Clofibrate results in increased expression of PPARA; Clofibrate results in increased expression of PPARA protein calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA protein]; calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA]; Tetradecanoylphorbol Acetate inhibits the reaction [Clofibrate results in increased expression of PPARA]
Cyclophosphamide results in decreased expression of SOX2 mRNA Panobinostat inhibits the reaction [Cyclophosphamide results in decreased expression of SOX2 mRNA]
Dichlorodiphenyl Dichloroethylene results in decreased expression of CYP11A1 mRNA Dichlorodiphenyl Dichloroethylene inhibits the reaction [Cholera Toxin results in increased expression of CYP11A1 mRNA]
Fenofibrate results in increased secretion of APOA1 protein Fenofibrate results in decreased expression of APOA1 mRNA Fenofibrate inhibits the reaction [APOA1 protein results in increased transport of Cholesterol]; Fenofibrate promotes the reaction [APOA1 protein results in increased transport of Cholesterol]
[Fenofibrate co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]
Gefitinib inhibits the reaction [FGF2 protein results in increased phosphorylation of FES protein]; Gefitinib inhibits the reaction [VEGFA protein results in increased phosphorylation of FES protein] Gefitinib results in decreased phosphorylation of FES protein
Hexachlorobenzene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Hexachlorobenzene results in decreased expression of and results in decreased secretion of ADIPOQ protein
Ketoconazole inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Ketoconazole inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone]; Ketoconazole inhibits the reaction [CYP3A29 protein results in increased oxidation of Nifedipine]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [etoxazole affects the phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CCL2 mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [titanium dioxide results in increased expression of CCL2 mRNA]
Methoxychlor results in increased expression of CYP11A1 mRNA Methoxychlor promotes the reaction [Cholera Toxin results in increased expression of CYP11A1 mRNA]
ochratoxin A results in increased expression of APAF1 mRNA; ochratoxin A results in increased expression of APAF1 protein fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 protein]
ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein] ochratoxin A results in increased expression of ATG5 protein
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA] ochratoxin A results in increased expression of BAX mRNA; ochratoxin A results in increased expression of BAX protein
[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA] ochratoxin A results in decreased expression of BCL2 mRNA; ochratoxin A results in decreased expression of BCL2 protein
BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein] ochratoxin A results in increased expression of BECN1 protein
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]; ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein; Taurine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]
3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein] ochratoxin A results in increased expression of CASP3 mRNA; ochratoxin A results in increased expression of CASP3 protein; ochratoxin A results in increased expression of CASP3 protein modified form
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein] ochratoxin A results in increased expression of CASP9 mRNA; ochratoxin A results in increased expression of CASP9 protein; ochratoxin A results in increased expression of CASP9 protein modified form
ochratoxin A results in decreased expression of CAT mRNA; ochratoxin A results in decreased expression of CAT protein Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]
ochratoxin A results in increased expression of DNMT1 mRNA; ochratoxin A results in increased expression of DNMT1 protein Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 protein]
ochratoxin A results in decreased expression of GCLC mRNA ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GCLC mRNA]
ochratoxin A results in decreased expression of GPX1 mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]
ochratoxin A results in decreased expression of GPX4 mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]
ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GSTA1 mRNA] ochratoxin A results in decreased expression of GSTA1 mRNA
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein]
Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 mRNA]; Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 protein] ochratoxin A results in increased expression of HDAC1 mRNA; ochratoxin A results in increased expression of HDAC1 protein
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]
ochratoxin A results in increased expression of IL6 mRNA NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]
ochratoxin A results in increased phosphorylation of MAPK1 protein ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]
ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] ochratoxin A results in increased phosphorylation of MAPK3 protein
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 protein]
ochratoxin A results in decreased expression of NEIL1 mRNA alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]
ochratoxin A results in decreased activity of NFE2L2 protein NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein]; ochratoxin A inhibits the reaction [sulforaphane affects the localization of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased expression of NFE2L2 mRNA] ochratoxin A results in decreased expression of NFE2L2 mRNA
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]
ochratoxin A results in increased expression of INOS mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of INOS mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of INOS mRNA]
ochratoxin A results in decreased expression of OGG1 mRNA alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]
ochratoxin A results in increased cleavage of PARP1 protein 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein] ochratoxin A results in increased expression of PARP1 protein
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PTGS2 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of PTGS2 mRNA]
ochratoxin A results in increased expression of PYCARD protein Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]
ochratoxin A results in increased expression of SOCS3 mRNA; ochratoxin A results in increased expression of SOCS3 protein Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 mRNA]; Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 protein]
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of SPP1 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of SPP1 mRNA]
Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of STAT3 protein]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein]
ochratoxin A results in increased expression of TGFB1 mRNA NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; sulforaphane inhibits the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] ochratoxin A results in increased secretion of TNF protein
Dietary Fats affects the reaction [Sodium Chloride affects the expression of FFAR1 mRNA]; Sodium Chloride affects the reaction [Dietary Fats affects the expression of FFAR1 mRNA]
sodium perchlorate inhibits the reaction [SLC5A5 protein alternative form results in increased uptake of Sodium Iodide]; sodium perchlorate inhibits the reaction [SLC5A5 protein results in increased uptake of Sodium Iodide]
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer inhibits the reaction [AGT protein results in increased secretion of Aldosterone]
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer inhibits the reaction [OPRK1 protein results in increased transport of Barium]
browse the term
